Phenotype-Based Discovery of Novel Drugs for Ocular Disease by Kennedy, Breandán
Proceedings of the British Pharmacological Society at http://www.pA2online.org/abstracts/Vol12Issue3abst276P.pdf 
Phenotype-Based Discovery of Novel Drugs for Ocular Disease. 
B KENNEDY. University College Dublin, Dublin, Ireland 
 
Our goal is to discover novel drugs with potential to improve the treatment of ocular 
disease. 
Vascular permeability, angiogenesis, inflammation and neurodegeneration are 
pathological hallmarks of prevalent forms of human blindness. Thus, we apply 
phenotype-based screens to identify novel drugs that modulate these disease 
hallmarks. 
A randomised library of ~3000 small molecule drugs was screened for anti-
angiogenic efficacy using the zebrafish hyaloid and inter-segmental developmental 
angiogenesis assays.  A hit molecule designated Quininib robustly inhibits 
developmental angiogenesis in zebrafish and was subsequently shown to reduce 
secretion of angiogenic and inflammatory factors from human colorectal tumour 
explants.  A hit series of Quininib analogs identified approximately 10 novel chemical 
entities with greater anti-angiogenic efficacy in the zebrafish model than the parent 
compound.  Here, data will be presented on the anti-angiogenic activity of the parent 
compound and NCE analogs in zebrafish, in tubule formation assays with human 
endothelial cells and in explant cultures of rodent aortic rings. Target profiling assays 
indicate that this novel Quininib series acts do not target VEGF receptors. 
Overall, phenotype based screens in zebrafish have identified a novel series of NCEs 
with robust anti-angiogenic activity that is retained in mammalian models.  This 
Quininib series appears not to target the VEGF receptors and thus offers potential to 
treat patients non-responsive to the current anti-VEGF treatments or to enhance 
efficacy in combination with anti-VEGF biologicals. 
 
